By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Cerus Corporation 

2411 Stanwell Drive

Concord  California  94520   U.S.A.
Phone: 925-288-6000 Fax: 925-288-6001


Medical Device



Company News
Ash Stevens To Manufacture Amotosalen Active Pharmaceutical Ingredient For Cerus Corporation (CERS)' INTERCEPT Blood System 1/28/2015 8:08:16 AM
Cerus Corporation (CERS) Prices $70.0 Million Public Offering Of Common Stock 1/7/2015 11:08:44 AM
Cerus Corporation (CERS) Announces Proposed Public Offering Of Common Stock 1/6/2015 9:57:07 AM
Cerus Corporation (CERS) Reports EU Phase 3 Clinical Trial Of INTERCEPT Red Blood Cells Met Primary Endpoint 1/5/2015 8:41:03 AM
Cerus Corporation (CERS) Reports U.S. Phase 2 Clinical Trial Of INTERCEPT Red Blood Cells Met Primary Endpoint 12/22/2014 11:12:42 AM
FDA Green Lights Cerus Corporation (CERS) System To Cut Blood Transfusion Infections 12/17/2014 6:59:22 AM
FDA Accepts IDE Supplement For Cerus Corporation (CERS)'s INTERCEPT Blood System Treatment Of Ebola Convalescent Plasma 11/21/2014 10:48:05 AM
Cerus Corporation (CERS) Reports Third Quarter 2014 Results 11/5/2014 9:52:15 AM
Cerus Corporation (CERS) Announces Agreement With Kawasumi Laboratories, Inc. For The Development Of INTERCEPT Platelets Kits In Japan 10/29/2014 8:44:24 AM
American Red Cross To Participate In Cerus Corporation (CERS)' IDE Study To Address Chikungunya And Dengue Blood Safety Risks 10/23/2014 10:13:43 AM